The FDA issued draft guidance Jan. 21 proposing the use of minimal residual disease and complete response as primary endpoints to support accelerated approval of drugs for multiple myeloma. The draft ...

BGE-102 has the potential for therapeutic retinal exposure with oral delivery, reducing treatment burden in ocular indications currently treated ...

National Clinical Trials Network (NCTN) group focused on improving outcomes for adults with cancer through multi-center clinical research, recently announced changes in leadership across multiple ...

- EMA provided overall agreement with the proposed Phase 3 clinical trial of VCN-01 in combination with gemcitabine/nab-paclitaxel for the first-line treatment of ...

The Food and Drug Administration (FDA) has issued a new guidance document entitled “Enhancing Participation in Clinical Trials – Eligibility Criteria, Enrollment Practices, and Trial Decision.” The ...

AI is assisting in trial design aspects such as patient selection and site location Argenica used UK group Brainomix to get its stroke trial program back on track Listed minnow Pathkey AI crunches ...

Oncology clinical trials drive some of the most important advances in medicine, yet they remain some of the most challenging to design and run. Intensive assessments, frequent amendments, complex ...

Improvements in medical therapy, carotid-artery stenting, and carotid endarterectomy call into question the preferred management of asymptomatic carotid stenosis. Whether adding revascularization to ...

TCT 704: Outcomes After LAAC Using a Fluoropolymer Coated Device in Patients of Historically Underrepresented Racial and Ethnic Groups: A Sub-analysis of the HEAL-LAA Post Approval Study Receive the ...

Oct 14 (Reuters) - U.S. biotech firm Nabla Bio said on Tuesday it has signed a second major research partnership with Japanese drugmaker Takeda Pharmaceutical (4502.T), opens new tab, deepening their ...